ThursdayMay 19, 2022 9:45 am

Flora Growth Corp. (NASDAQ: FLGC), A Company Revolutionizing the Plant-Based Wellness and Lifestyle Industry

Flora Growth has been building a design-led collective of plant-based wellness and lifestyle brands Through the work done by its pharma division, the company earned over $31.5 million in gross proceeds in the year ended November 2021 The company still maintains its revenue guidance projection of $35-45 million for 2022, attributed mainly to product diversification initiatives, strengthening its supply chain, and adoption of cost-effective cultivation practices Since its inception, Flora Growth (NASDAQ: FLGC) has remained committed to building a design-led collective of plant-based wellness and lifestyle brands. This objective has defined Flora Growth’s three central pillars- wholesale cannabis, pharmaceutical cannabis,…

Continue Reading

TuesdayMay 17, 2022 10:30 am

Flora Growth Corp. (NASDAQ: FLGC) Bolsters its Board of Directors following Tim Leslie’s Addition and Luis Merchan’s Appointment as Chairman

Luis Merchan, Flora Growth’s CEO, will serve as the new Chairman of the Board Tim Leslie, the Chairman of the company’s Advisory Board, will serve on its Board and audit committee Flora Growth’s management is confident that these changes will position it as a U.S-based issuer while increasing its access to U.S-based investment Since the beginning of 2022, Flora Growth (NASDAQ: FLGC) has been making strategic moves that strengthen its human resources and reinforce its executive team.  The company kicked off the year with the appointment of Tim Leslie as the Chairman of its newly formed Advisory Board (https://cnw.fm/suiqd).  Later,…

Continue Reading

WednesdayMay 11, 2022 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry

Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance  Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of…

Continue Reading

MondayMay 09, 2022 9:45 am

Advanced Container Technologies Inc. (ACTX) Offers New Tech with GrowPod Automated, Indoor Micro-Farms

Innovators in food supply field have been developing new technologies such as indoor farms These game-changing micro-farms can be built anywhere ACTX is the exclusive distributor of GrowPods in the United States With global supply chain issues grabbing headlines and impacting almost every industry, potential solutions in any sector are certain to capture attention. Hence Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of GrowPods, is definitely seeing interest in the environmentally controlled micro-farms that allow cultivation of ultraclean crops year-round.  “Land preservation and regenerative organic agriculture practices are critical to solving food insecurity and combating climate change,” reported…

Continue Reading

ThursdayMay 05, 2022 12:25 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands

In its most recent oral nicotine study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls Lexaria hopes to evidence in its upcoming human oral nicotine study NIC-H22-1, that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to currently sold brands Lexaria’s DehydraTECH technology works with new and existing drugs, processing them into a final form that increases bioavailability, speeds up onset and improves effectiveness that can allow for smaller doses  The company also recently announced…

Continue Reading

TuesdayMay 03, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Update on its Patented DehydraTECH(TM) Technology, Including the Approval of New Patent

Lexaria received its 25th patent – and the first patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs The company is seeking IND approval from the FDA and has commenced its human HYPER-H21-4 study for hypertension with DehydraTECH-CBD, with results expected in Q3 2022 Lexaria is also commencing its human oral nicotine study, NIC-H22-1 to compare Lexaria's DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the US such as ON! and Zyn Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced some positive news that further promotes…

Continue Reading

MondayMay 02, 2022 9:30 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Strengthens Financial Profile with Debt Reduction, Adjustments to Revenue Strategy

Red White & Bloom Brands is a multi-state cannabis operator based in Canada and focused on developing revenue opportunities in strong U.S. cannabis markets such as Michigan, Florida and California The company recently announced it has eliminated $115 million in debt liabilities as part of its efforts to streamline its financial operations during a period when many companies are struggling with the effects of the COVID pandemic Red White & Bloom’s debt reduction includes cutting over $22 million in annual expenses The company has solidified its foothold in Michigan with acquisitions that have allowed it to become vertically integrated and…

Continue Reading

FridayApr 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH

Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S. It adds to the company’s growing patent portfolio, which also consists of ~50 pending patents worldwide Over the 2022 calendar year, the company seeks to also pursue regulatory and commercial advancement In 2016, Lexaria Bioscience (NASDAQ: LEXX) received its first United States patent grant and over the years, the company has been aggressive at broadening its patent suite, a move which it has attributed to refining the patent claims…

Continue Reading

FridayApr 29, 2022 9:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Extends Michigan Expansion with Debut of Platinum Vape Live Resin; Announces Plans to Release Full-Year 2021 Results on May 2

Red White & Bloom and its wholly owned subsidiary RWB Michigan LLC recently announced the rollout of Platinum Vape(TM) Live Resin in Michigan The debut marks the company’s entry into the live resin in Michigan, which yield higher margins than the company’s existing distillate vape products RWB expects to release its full-year 2021 results on May 2, with the management hosting a conference call on May 3 Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator on a mission to become the most recognizable cannabis company in the United States, is celebrating the fulfillment of its…

Continue Reading

WednesdayApr 27, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data

Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs  Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977